Immunomodulating antibodies and drugs for the treatment of hematological malignancies

Cancer and Metastasis Reviews

Volumn 30, Issue 1, 2011, Pages 97-109

  Houot, Roch ^a   Kohrt, Holbrook ^b   Goldstein, Matthew J ^b   Levy, Ronald ^b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; CpG; Cytokine; Hematological malignancies; Immunomodulation; Immunotherapy; Lenalidomide; Leukemia; Lymphoma; Monoclonal antibodies; Myeloma; Thalidomide

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLINATUMOMAB; CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CT 011; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACETUZUMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 21; IPILIMUMAB; LENALIDOMIDE; LUCATUMUMAB; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY;

EID: 79952283445     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-011-9274-3     Document Type: Article

References (120)

1. W Zou 2005 Immunosuppressive networks in the tumour environment and their therapeutic relevance Nature Reviews. Cancer 5 263 274 15776005 1:CAS:528:DC%2BD2MXivVars7g%3D (Pubitemid 40488632)
2. G Cartron H Watier J Golay P Solal-Celigny 2004 From the bench to the bedside: Ways to improve rituximab efficacy Blood 104 2635 2642 15226177 1:CAS:528:DC%2BD2cXpslKjs70%3D (Pubitemid 39434941)
3. B Coiffier E Lepage J Briere, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma The New England Journal of Medicine 346 235 242 11807147 1:CAS:528:DC%2BD38XmslGgsw%3D%3D (Pubitemid 34438862)
4. M Boyiadzis KA Foon 2008 Approved monoclonal antibodies for cancer therapy Expert Opinion on Biological Therapy 8 1151 1158 18613766 1:CAS:528:DC%2BD1cXos1Chtro%3D
5. I Melero S Hervas-Stubbs M Glennie DM Pardoll L Chen 2007 Immunostimulatory monoclonal antibodies for cancer therapy Nature Reviews. Cancer 7 95 106 17251916 1:CAS:528:DC%2BD2sXotFOjtQ%3D%3D (Pubitemid 46160986)
6. G Suntharalingam MR Perry S Ward, et al. 2006 Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 The New England Journal of Medicine 355 1018 1028 16908486 1:CAS:528:DC%2BD28XpsFKmtbc%3D (Pubitemid 44343545)
7. T Uno K Takeda Y Kojima, et al. 2006 Eradication of established tumors in mice by a combination antibody-based therapy Natural Medicines 12 693 698 1:CAS:528:DC%2BD28XltlOjsb4%3D (Pubitemid 43865240)
8. Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., et al. (2010) CD137 stimulation enhances the anti-lymphoma activity of anti-CD20 antibodies. Blood, doi: 10.1182/blood-2010-08-301945.
9. Srivastava, S., Feng, H., Zhang, S., Liang, J., Squiban, P., Farag, S. (2009) Enhancing natural 651 killer (NK) cell mediated killing of non-Hodgkin's lymphoma. ASH Annual Meeting Abstracts, 114, 2706.
10. JG Egen MS Kuhns JP Allison 2002 CTLA-4: New insights into its biological function and use in tumor immunotherapy Nature Immunology 3 611 618 12087419 1:CAS:528:DC%2BD38Xksl2mtbs%3D (Pubitemid 34752469)
11. W Zou 2006 Regulatory T cells, tumour immunity and immunotherapy Nature Reviews. Immunology 6 295 307 16557261 1:CAS:528:DC%2BD28XivVyru7k%3D
12. FS Hodi SJ O'Day DF McDermott, et al. 2010 Improved survival with ipilimumab in patients with metastatic melanoma New England Journal of Medicine 363 711 723 20525992 1:CAS:528:DC%2BC3cXhtVCrtrbN
13. L Chen 2004 Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity Nature Reviews. Immunology 4 336 347 15122199 1:CAS:528:DC%2BD2cXjsFChsrY%3D (Pubitemid 38649276)
14. JA Brown DM Dorfman FR Ma, et al. 2003 Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production Journal of Immunology 170 1257 1266 1:CAS:528:DC%2BD3sXnvVOmtQ%3D%3D (Pubitemid 36139491)
15. HR Salih S Wintterle M Krusch, et al. 2006 The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans Experimental Hematology 34 888 894 16797416 1:CAS:528:DC%2BD28XlvFGru74%3D
16. L Xerri B Chetaille N Seriari, et al. 2008 Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia Human Pathology 39 1050 1058 18479731 1:CAS:528:DC%2BD1cXnsF2qu78%3D
17. H Tamura K Dan K Tamada, et al. 2005 Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia Clinical Cancer Research 11 5708 5717 16115907 1:CAS:528:DC%2BD2MXos1CjsLk%3D (Pubitemid 41170294)
18. X Chen S Liu L Wang W Zhang Y Ji X Ma 2008 Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia Cancer Biology & Therapy 7 622 627 1:CAS:528:DC%2BD1cXhtVeisLvI
19. Y Iwai M Ishida Y Tanaka T Okazaki T Honjo N Minato 2002 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proceedings of the National Academy of Sciences of the United States of America 99 12293 12297 12218188 1:CAS:528: DC%2BD38XntlCksL8%3D
20. C Blank I Brown AC Peterson, et al. 2004 PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells Cancer Research 64 1140 1145 14871849 1:CAS:528:DC%2BD2cXhtFCgtrs%3D (Pubitemid 38176921)
21. SE Strome H Dong H Tamura, et al. 2003 B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Research 63 6501 6505 14559843 1:CAS:528:DC%2BD3sXotV2is7c%3D (Pubitemid 37255203)
22. B Hardy R Kovjazin A Raiter N Ganor A Novogrodsky 1997 A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice Proceedings of the National Academy of Sciences of the United States of America 94 5756 5760 9159146 1:CAS:528:DyaK2sXjsFKqtLk%3D (Pubitemid 27241843)
23. B Hardy I Yampolski R Kovjazin M Galli A Novogrodsky 1994 A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice Cancer Research 54 5793 5796 7954401 1:CAS:528:DyaK2cXmvFykurk%3D (Pubitemid 24375206)
24. R Berger R Rotem-Yehudar G Slama, et al. 2008 Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clinical Cancer Research 14 3044 3051 18483370 1:CAS:528:DC%2BD1cXmtVCmtbw%3D
25. JR Westin F Chu M Foglietta R Rotem-Yehudar SS Neelapu 2010 Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma Journal of Clinical Oncology 28 15s
26. JR Brahmer CG Drake I Wollner, et al. 2010 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates Journal of Clinical Oncology 28 19 3167 3175 20516446 1:CAS:528:DC%2BC3cXpslajtLw%3D
27. SA Quezada LZ Jarvinen EF Lind RJ Noelle 2004 CD40/CD154 interactions at the interface of tolerance and immunity Annual Review of Immunology 22 307 328 15032580 1:CAS:528:DC%2BD2cXktlOgs7g%3D (Pubitemid 38680425)
28. HJ Gruss SK Dower 1995 Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas Blood 85 3378 3404 7780126 1:CAS:528:DyaK2MXmtlOmtrs%3D
29. HJ Gruss F Herrmann V Gattei A Gloghini A Pinto A Carbone 1997 CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues Leukaemia & Lymphoma 24 393 422 1:CAS:528:DyaK1MXislCjtbY%3D (Pubitemid 27182198)
30. FM Uckun K Gajl-Peczalska DE Myers W Jaszcz S Haissig JA Ledbetter 1990 Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells Blood 76 2449 2456 1702326 1:STN:280:DyaK3M%2FptFCrsw%3D%3D
31. M Cella D Scheidegger K Palmer-Lehmann P Lane A Lanzavecchia G Alber 1996 Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation The Journal of Experimental Medicine 184 747 752 8760829 1:CAS:528:DyaK28XltVCrsbc%3D (Pubitemid 26324129)
32. RH Vonderheide KT Flaherty M Khalil, et al. 2007 Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody Journal of Clinical Oncology 25 876 883 17327609 1:CAS:528:DC%2BD2sXjvVKmtLk%3D (Pubitemid 350002889)
33. R Advani A Forero-Torres RR Furman, et al. 2009 Phase I study of the humanized antiCD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma Journal of Clinical Oncology 27 4371 4377 19636010 1:CAS:528:DC%2BD1MXht1WisbnN
34. RR Furman A Forero-Torres A Shustov JG Drachman 2010 A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia Leukemia and Lymphoma 51 228 235 20038235 1:CAS:528:DC%2BC3cXhtlyrtr0%3D
35. M Hussein JR Berenson R Niesvizky, et al. 2010 A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma Haematologica 95 845 848 20133895 1:CAS:528: DC%2BC3cXht1yrsbzF
36. M Luqman S Klabunde K Lin, et al. 2008 The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells Blood 112 711 720 18497318 1:CAS:528:DC%2BD1cXpsVaisr0%3D
37. Byrd, J., Flinn, I., Khan, K., et al. (2006). Pharmacokinetics and pharmacodynamics from a firstin-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory Chronic Lymphocytic Leukemia. Blood, 108; abstract 3575.
38. Bensinger, W., Jagannath, S., Becker, P., et al. (2006). A phase 1 dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory multiple myeloma. Blood, 108; abstract 3575.
39. I Melero WW Shuford SA Newby, et al. 1997 Monoclonal antibodies against the 4-1BB Tcell activation molecule eradicate established tumors Natural Medicines 3 682 685 1:CAS:528:DyaK2sXjsFOhtr8%3D (Pubitemid 27264981)
40. H Narazaki Y Zhu L Luo G Zhu L Chen 2010 CD137 agonist antibody prevents cancer recurrence: Contribution of CD137 on both hematopoietic and non-hematopoietic cells Blood 115 10 1941 1948 20068221 1:CAS:528: DC%2BC3cXhtFensbbN
41. I Melero JV Johnston WW Shufford RS Mittler L Chen 1998 NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies Cellular Immunology 190 167 172 9878117 1:CAS:528:DyaK1MXhslWhuw%3D%3D (Pubitemid 29011104)
42. RA Wilcox AI Chapoval KS Gorski, et al. 2002 Cutting edge: Expression of functional CD137 receptor by dendritic cells Journal of Immunology 168 4262 4267 1:CAS:528:DC%2BD38Xjt12jsLw%3D (Pubitemid 34441322)
43. Sznol, M., Hodi, F. S., Margolin, K., et al. (2008) Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol.;26 (2008 ASCO Annual Meeting).
44. R Houot MJ Goldstein HE Kohrt, et al. 2009 Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion Blood 114 3431 3438 19641184 1:CAS:528:DC%2BD1MXhtlensb7K
45. O Murillo A Arina S Hervas-Stubbs, et al. 2008 Therapeutic antitumor efficacy of antiCD137 agonistic monoclonal antibody in mouse models of myeloma Clinical Cancer Research 14 6895 6906 18980984 1:CAS:528:DC%2BD1cXhtlens7nJ
46. M Goebeler A Viardot R Noppeney, et al. 2010 CD3/CD19 bispecific BiTE antibody blinatumomab treatment of non-Hodgkin lymphoma (NHL) patients: 60 μg/m2/d by continuous infusion is tolerable and results in durable responses Heamatologica 95 s2 230
47. R Bargou E Leo G Zugmaier, et al. 2008 Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 974 977 18703743 1:CAS:528:DC%2BD1cXpslWru70%3D
48. Topp, M. S., Zugmaier, G., Goekbuget, N., et al. (2009). Report of a phase II trial of single-agent BiTE® antibody Blinatumomab in patients with minimal residual disease (MRD) positive Bprecursor acute lymphoblastic leukemia (ALL). Blood, 114: abstract 840.
49. BK Link ZK Ballas D Weisdorf, et al. 2006 Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma Journal of Immunotherapy 29 558 568 16971811 1:CAS:528:DC%2BD28XpsVantb8%3D (Pubitemid 44395280)
50. T Decker F Schneller T Sparwasser, et al. 2000 Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells Blood 95 999 1006 10648415 1:CAS:528:DC%2BD3cXotV2guw%3D%3D (Pubitemid 30062724)
51. B Jahrsdorfer G Hartmann E Racila, et al. 2001 CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens Journal of Leukocyte Biology 69 81 88 11200072 1:CAS:528:DC%2BD3MXlvFChsw%3D%3D (Pubitemid 32095121)
52. E Moga E Alvarez E Canto, et al. 2008 NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma Experimental Hematology 36 69 77 17959301 1:CAS:528:DC%2BD2sXhsVOrtrzI (Pubitemid 350266964)
53. JW Friedberg H Kim M McCauley, et al. 2005 Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon-alpha/beta-inducible gene expression, without significant toxicity Blood 105 489 495 15358617 1:CAS:528:DC%2BD2MXltlGisg%3D%3D (Pubitemid 40070726)
54. JP Leonard BK Link C Emmanouilides, et al. 2007 Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma Clinical Cancer Research 13 6168 6174 17947483 1:CAS:528:DC%2BD2sXhtFygsL7E (Pubitemid 350075077)
55. JW Friedberg JL Kelly D Neuberg, et al. 2009 Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma British Journal Haematology 146 282 291 1:CAS:528: DC%2BD1MXhtValurrL
56. JD Brody WZ Ai DK Czerwinski, et al. 2010 In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II Study Journal of Clinical Oncology 28 28 4324 4332 20697067
57. J Li W Song DK Czerwinski, et al. 2007 Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself Journal of Immunology 179 2493 2500 1:CAS:528:DC%2BD2sXosVyqsb4%3D
58. S Singhal J Mehta R Desikan, et al. 1999 Antitumor activity of thalidomide in refractory multiple myeloma The New England Journal of Medicine 341 1565 1571 10564685 1:CAS:528:DyaK1MXotVSgs78%3D
59. M Dimopoulos A Spencer M Attal, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma The New England Journal of Medicine 357 2123 2132 18032762 1:CAS:528:DC%2BD2sXhtlGis7nN (Pubitemid 350146107)
60. DM Weber C Chen R Niesvizky, et al. 2007 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America The New England Journal of Medicine 357 2133 2142 18032763 1:CAS:528:DC%2BD2sXhtlGis7bM (Pubitemid 350146108)
61. SM Smith D Grinblatt JL Johnson, et al. 2008 Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: A phase II trial of the cancer and leukemia group B British Journal Haematology 140 313 319 1:CAS:528:DC%2BD1cXitlakt7s%3D (Pubitemid 351209487)
62. H Kaufmann M Raderer S Wohrer, et al. 2004 Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood 104 2269 2271 15166030 1:CAS:528:DC%2BD2cXovVegtr4%3D (Pubitemid 39331822)
63. SP Treon JD Soumerai AR Branagan, et al. 2008 Thalidomide and rituximab in Waldenstrom macroglobulinemia Blood 112 4452 4457 18713945 1:CAS:528:DC%2BD1cXhsVCltb3N
64. A Chanan-Khan KC Miller L Musial, et al. 2006 Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study Journal of Clinical Oncology 24 5343 5349 17088571 1:CAS:528:DC%2BD2sXisVSjtg%3D%3D (Pubitemid 46623164)
65. A Ferrajoli BN Lee EJ Schlette, et al. 2008 Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia Blood 111 5291 5297 18334676 1:CAS:528:DC%2BD1cXntFWnsr4%3D
66. A List G Dewald J Bennett, et al. 2006 Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion The New England Journal of Medicine 355 1456 1465 17021321 1:CAS:528:DC%2BD28XhtVGgtrvO (Pubitemid 44511560)
67. PH Wiernik 2009 Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs) Current Treatment Options in Oncology 10 1 15 19016330
68. TE Witzig PH Wiernik T Moore, et al. 2009 Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 27 5404 5409 19805688 1:CAS:528: DC%2BD1MXhsFKkt7vN
69. TM Habermann IS Lossos G Justice, et al. 2009 Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma British Journal Haematology 145 344 349 1:CAS:528:DC%2BD1MXlslOhsrc%3D
70. BL Ebert N Galili P Tamayo, et al. 2008 An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome PLoS Medicine 5 e35 18271621
71. LA Andritsos AJ Johnson G Lozanski, et al. 2008 Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia Journal of Clinical Oncology 26 2519 2525 18427150 1:CAS:528: DC%2BD1cXnsVKhurg%3D
72. B Boll P Borchmann MS Topp, et al. 2010 Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma British Journal of Haematology 148 480 482 19863533
73. G Corazzelli R De Filippi G Capobianco, et al. 2009 Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma American Journal of Hematology 85 87 90
74. G Dueck N Chua A Prasad, et al. 2010 Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma Cancer 116 19 4541 4548 20572046 1:CAS:528:DC%2BC3cXht1KnsLrJ
75. L Wu M Adams T Carter, et al. 2008 lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells Clinical Cancer Research 14 4650 4657 18628480 1:CAS:528:DC%2BD1cXosFGiur8%3D
76. R Lapalombella B Yu G Triantafillou, et al. 2008 Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells Blood 112 5180 5189 18772452 1:CAS:528:DC%2BD1cXhsFWms7vI
77. FJ Hernandez-Ilizaliturri N Reddy B Holkova E Ottman MS Czuczman 2005 Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model Clinical Cancer Research 11 59845992
78. SP Treon JD Soumerai AR Branagan, et al. 2009 Lenalidomide and rituximab in Waldenstrom's macroglobulinemia Clinical Cancer Research 15 355 360 19118065 1:CAS:528:DC%2BD1MXhs1eqtw%3D%3D
79. Wang, L., Fayad, L., Hagemeister, F. B., et al. (2009). A Phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma. ASH meeting, Abstr 2719.
80. Dutia, M., DeRoock, I., Chee, K., et al. (2010). Analysis of a phase 2 study of lenalidomide and rituximab in relapsed or refractory non-Hodgkin's lymphoma. EHA meeting, abst # 0295.
81. NH Fowler P McLaughlin FB Hagemeister, et al. 2010 Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-hodgkin's lymphoma Journal of Clinical Oncology 28 15s
82. GL Plosker DP Figgitt 2003 Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia Drugs 63 803 843 12662126 1:CAS:528:DC%2BD3sXjsF2gtbw%3D (Pubitemid 36432084)
83. P McLaughlin AJ Grillo-Lopez BK Link, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program Journal of Clinical Oncology 16 2825 2833 9704735 1:CAS:528:DyaK1cXlsFCgu7c%3D (Pubitemid 28363048)
84. SA Rosenberg MT Lotze LM Muul, et al. 1987 A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone The New England Journal of Medicine 316 889 897 3493432 1:STN:280:DyaL2s7ksVGitA%3D%3D (Pubitemid 17041979)
85. CF Eisenbeis A Grainger B Fischer, et al. 2004 Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study Clinical Cancer Research 10 6101 6110 15447996 1:CAS:528:DC%2BD2cXnvVOjsrY%3D (Pubitemid 39287515)
86. JW Friedberg D Neuberg JG Gribben, et al. 2002 Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma British Journal Haematology 117 828 834 1:CAS:528:DC%2BD38XlvVWjsrs%3D (Pubitemid 34639243)
87. WL Gluck D Hurst A Yuen, et al. 2004 Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response Clinical Cancer Research 10 2253 2264 15073100 1:CAS:528:DC%2BD2cXivFSqsrw%3D (Pubitemid 38445682)
88. KD Khan C Emmanouilides DM Benson Jr, et al. 2006 A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma Clinical Cancer Research 12 7046 7053 17145827 1:CAS:528:DC%2BD28Xht1Kns7nM (Pubitemid 44974502)
89. RE Banks PM Patel PJ Selby 1995 Interleukin 12: A new clinical player in cytokine therapy British Journal of Cancer 71 655 659 7710924 1:CAS:528:DyaK2MXmtF2ks7c%3D
90. A Younes B Pro MJ Robertson, et al. 2004 Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease Clinical Cancer Research 10 5432 5438 15328181 1:CAS:528:DC%2BD2cXmvFSltLo%3D (Pubitemid 39100480)
91. SM Ansell SM Geyer MJ Maurer, et al. 2006 Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients Clinical Cancer Research 12 6056 6063 17062681 1:CAS:528:DC%2BD28XhtFWhsbnM (Pubitemid 44703769)
92. DJ Andorsky JM Timmerman 2008 Interleukin-21: Biology and application to cancer therapy Expert Opinion on Biological Therapy 8 1295 1307 18694350 1:CAS:528:DC%2BD1cXpslart7o%3D
93. JM Roda T Joshi JP Butchar, et al. 2007 The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines Clinical Cancer Research 13 6419 6428 17962339 1:CAS:528:DC%2BD2sXht1CgtbzI (Pubitemid 350075032)
94. LA VanderMolen RG Steis PL Duffey, et al. 1990 Low-versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma Journal of the National Cancer Institute 82 235 238 2296053 1:STN:280:DyaK3c7ht1Crtw%3D%3D (Pubitemid 20079997)
95. S Sacchi M Federico U Vitolo, et al. 2001 Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma Haematologica 86 951 958 11532623 1:CAS:528:DC%2BD3MXotlGitbk%3D (Pubitemid 32937704)
96. TA Davis DG Maloney AJ Grillo-Lopez, et al. 2000 Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a Clinical Cancer Research 6 2644 2652 10914705 1:CAS:528:DC%2BD3cXlslentrY%3D (Pubitemid 30482099)
97. E Kimby J Jurlander C Geisler, et al. 2008 Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group Leukaemia & Lymphoma 49 102 112 1:CAS:528: DC%2BD1cXnsFequw%3D%3D (Pubitemid 351146889)
98. LE van der Kolk AJ Grillo-Lopez JW Baars MH van Oers 2003 Treatment of relapsed Bcell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy Leukemia 17 1658 1664 12886256 (Pubitemid 36986970)
99. G Cartron L Zhao-Yang M Baudard, et al. 2008 Granulocyte-macrophage colonystimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: Results of a phase II study Journal of Clinical Oncology 26 2725 2731 18427151 1:CAS:528:DC%2BD1cXnvVOhsbk%3D
100. JD Hainsworth S Litchy JH Barton, et al. 2003 Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology 21 1746 1751 12721250 1:CAS:528:DC%2BD2cXpsVWqtr8%3D (Pubitemid 46638587)
101. D Huhn C von Schilling M Wilhelm, et al. 2001 Rituximab therapy of patients with B-cell chronic lymphocytic leukemia Blood 98 1326 1331 11520778 1:CAS:528:DC%2BD3MXmvFGjtro%3D
102. M Itala CH Geisler E Kimby, et al. 2002 Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study European Journal of Haematology 69 129 134 12406005 1:CAS:528:DC%2BD38XpsVWgs7k%3D (Pubitemid 35335149)
103. P McLaughlin N Liu N Poindexter, et al. 2005 Rituximab plus GM-CSF (Leukine) for indolent lymphoma. Proceedings of the 9th International Conference on Malignant lymphomas Annals of Oncology 16 v68
104. J Kjaergaard J Tanaka JA Kim K Rothchild A Weinberg S Shu 2000 Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth Cancer Research 60 5514 5521 11034096 1:CAS:528:DC%2BD3cXns1eht78%3D
105. S Piconese B Valzasina MP Colombo 2008 OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection The Journal of Experimental Medicine 205 825 839 18362171 1:CAS:528:DC%2BD1cXkvVyrsrg%3D (Pubitemid 351549881)
106. AD Weinberg MM Rivera R Prell, et al. 2000 Engagement of the OX-40 receptor in vivo enhances antitumor immunity Journal of Immunology 164 2160 2169 1:CAS:528:DC%2BD3cXhtlymu7g%3D (Pubitemid 30108775)
107. K Ko S Yamazaki K Nakamura, et al. 2005 Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells The Journal of Experimental Medicine 202 885 891 16186187 1:CAS:528:DC%2BD2MXhtVygt73I (Pubitemid 41396888)
108. RR French VY Taraban GR Crowther, et al. 2007 Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation Blood 109 4810 4815 17311995 1:CAS:528:DC%2BD2sXmt1Ogur0%3D (Pubitemid 46827776)
109. T Sakanishi H Yagita 2010 Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice Biochemical and Biophysical Research Communications 393 829 835 20171165 1:CAS:528:DC%2BC3cXjs1Ontbc%3D
110. ED Kwon AA Hurwitz BA Foster, et al. 1997 Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer Proceedings of the National Academy of Sciences of the United States of America 94 8099 8103 9223321 1:CAS:528:DyaK2sXksl2ltrk%3D (Pubitemid 27343783)
111. DR Leach MF Krummel JP Allison 1996 Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1734 1736 8596936 1:CAS:528:DyaK28XhvVWmsLk%3D (Pubitemid 26102823)
112. F Hirano K Kaneko H Tamura, et al. 2005 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Research 65 1089 1096 15705911 1:CAS:528:DC%2BD2MXhtVWnurg%3D (Pubitemid 40216472)
113. RR French HT Chan AL Tutt MJ Glennie 1999 CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help Natural Medicines 5 548 553 1:CAS:528:DyaK1MXivVKrs7g%3D (Pubitemid 29220214)
114. CL Law KA Gordon J Collier, et al. 2005 Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40 Cancer Research 65 8331 8338 16166310 1:CAS:528:DC%2BD2MXhtVShsbnO (Pubitemid 41330598)
115. F Romagne P Andre P Spee, et al. 2009 Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells Blood 114 2667 2677 19553639 1:CAS:528:DC%2BD1MXht1eit7vL
116. D O'Mahony JC Morris C Quinn, et al. 2007 A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clinical Cancer Research 13 958 964 17289891 (Pubitemid 46340373)
117. A Bashey B Medina S Corringham, et al. 2009 CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation Blood 113 1581 1588 18974373 1:CAS:528:DC%2BD1MXitlCrtbk%3D
118. SM Ansell SA Hurvitz PA Koenig, et al. 2009 Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma Clinical Cancer Research 15 6446 6453 19808874 1:CAS:528:DC%2BD1MXhtlyqsbzN
119. SM Ansell TE Witzig PJ Kurtin, et al. 2002 Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma Blood 99 67 74 11756154 1:CAS:528:DC%2BD38XivF2jtA%3D%3D
120. A Ferrajoli 2009 Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia Leukaemia & Lymphoma 50 514 516 1:CAS:528:DC%2BD1MXktVKisbY%3D